Approaches to safety regulations-particularly radiation safety regulations-must be founded on the very best science possible. However, radiation safety regulations always lag behind the science for a number of reasons. First, the normal scientific process of peer-review, debate, and confirmation must ensure that the conclusions are indeed correct, the implications of the research are fully understood, and a consensus has been established. Second, in the U.S., there is a well-established, all-inclusive political process that leads to changes in radiation safety regulations. This process can take a very long time, as was demonstrated when the process was initiated to change the Code of Federal Regulations more than 20 y ago in response to International Commission on Radiation Protection Publication 26 and other recommendations. Currently, we find ourselves in a situation where the possibility of a terrorist radiological attack may occur and where the existing body of regulations provides very little guidance. Many international and national bodies, including several federal agencies, have provided recommendations on the appropriate levels of exposure for first-responders and first-receivers, as well as for the general public. However, some agencies provide guidelines based on very conservative dose limits which are not appropriate in situations where there is a substantial chance for the loss of lives and critical infrastructure. It is important that an emergency response is not hampered by overly cautious guidelines or regulations. In a number of exercises the impact of disparate guidelines and training in radiological situations has highlighted the need for clear reasonable limits that maximize the benefit from an emergency response and for any cleanup after the incident. This presentation will focus first on the federal infrastructure established to respond to radiological accidents and incidents. It will review briefly the major recommendations, both international and national, for responders and will attempt, where possible, to establish the scientific foundation for these guidelines. We will also stress the need to clearly and openly communicate the recommendations to the first-responders and the public so that no unnecessary anxiety or associated actions on their part impedes the ability to respond to a disaster. Finally, the use of these guidelines and recommendations by decision-makers at all levels will be discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/HP.0b013e3181b0c06d | DOI Listing |
Radiat Oncol
January 2025
Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan.
Introduction: Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic disease, including the primary lesion and lymph node metastases, combined with local consolidative therapy (LCT) for oligometastases.
Methods: This was a multicenter Phase II trial for patients with Stage IV NSCLC with oligometastases for whom CRT for thoracic disease was feasible.
J Immunother Cancer
January 2025
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Background: Immune checkpoint inhibitors (ICIs) in combination with antiangiogenic drugs have shown promising outcomes in the third-line and subsequent treatments of patients with microsatellite stable metastatic colorectal cancer (MSS-mCRC). Radiotherapy (RT) may enhance the antitumor effect of immunotherapy. However, the effect of RT exposure on patients receiving ICIs and targeted therapy remains unclear.
View Article and Find Full Text PDFJ Thorac Oncol
January 2025
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:
Introduction: Treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with disease progression on/after osimertinib and platinum-based chemotherapy are limited.
Methods: CHRYSALIS-2 Cohort A evaluated amivantamab+lazertinib in patients with EGFR exon 19 deletion- or L858R-mutated NSCLC with disease progression on/after osimertinib and platinum-based chemotherapy. Primary endpoint was investigator-assessed objective response rate (ORR).
Sci Rep
January 2025
Department of Medical Laboratory Technology, Faculty of Applied Health Sciences Technology, Badr University in Cairo (BUC), Badr city, Cairo, Egypt.
Cancer and microbial infections place a significant burden on the world's health systems and can increase the rate of disease and mortality. In the current study, a novel nanocomposite based on Gum Arabic, silver and copper oxide nanoparticles (GA@Ag-CuO nanocomposite) was synthesized to overcome the problem of microbial infection and in cancer treatment. Characterization using UV-Vis.
View Article and Find Full Text PDFJ Nucl Med
January 2025
Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts;
Radionuclides used for imaging and therapy can show high molecular specificity in the body with appropriate targeting ligands. We hypothesized that local energy delivered by molecularly targeted radionuclides could chemically activate prodrugs at disease sites while avoiding activation in off-target sites of toxicity. As proof of principle, we tested whether this strategy of radionuclide-induced drug engagement for release (RAiDER) could locally deliver combined radiation and chemotherapy to maximize tumor cytotoxicity while minimizing off-target exposure to activated chemotherapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!